Advertisement

pp 1-17 | Cite as

Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094)

  • Jeffrey M. WitkinEmail author
  • Tanya L. Wallace
  • William J. Martin
Chapter
Part of the Handbook of Experimental Pharmacology book series

Abstract

Conventional antidepressants increase the efflux of biogenic amine neurotransmitters (the monoamine hypothesis of depression) in the central nervous system (CNS) and are the principle drugs used to treat major depressive disorder (MDD). However, the lack of efficacy in some patients, the slow onset of action, and the side effect profiles of existing antidepressants necessitate the exploration of additional treatment options. The discovery of the nociceptin/orphanin FQ peptide NOP receptor (N/OFQ-NOP receptor) system and its characterization in preclinical biological and pharmacological stress-related conditions supports the potential antidepressant and anti-stress properties of a NOP receptor antagonist for the treatment of neurobehavioral disorders. BTRX-246040 (formerly LY2940094) was designed to test this hypothesis in the clinic. A small clinical proof of concept study demonstrated efficacy of BTRX-246040 in MDD patients. In this study, BTRX-246040 (40 mg, p.o.) significantly reduced negative bias as assessed by the facial recognition test within 1 week of treatment and decreased depression symptoms after 8 weeks. BTRX-246040 also reduced depression symptoms in a second trial with heavy alcohol drinkers. Given the comorbidity of MDD and alcohol use disorder, a compound with such effects in patients could be a valuable addition to the medications available. A proof of concept study showed efficacy of BTRX-246040 in reducing heavy drinking and increasing the probability of abstinence in individuals diagnosed with alcohol dependence. In addition, plasma levels of gamma-glutamyl transferase were decreased by BTRX-246040 compared to placebo control implying improvement in liver function. Collectively, the clinical data reviewed within this chapter suggest that BTRX-264040 functions to normalize dysfunction in reward circuits. The overall efficacy and safety of this compound with a novel mechanism of action are encouraging of further clinical development. BTRX-246040 is currently under development for MDD by BlackThorn Therapeutics.

Keywords

Alcohol use disorder Antidepressant BTRX-246040 LY2940094 Major depressive disorder N/OFQ NOP receptor antagonist Reward processing 

Abbreviations

AUD

Alcohol use disorder

BTRX-246040 = LY2940094

[2-[4-[(2-chloro-4,4-difluoro-spiro[5Hthieno[2,3-c]pyran-7,4′-piperidine]-1′-yl)methyl]-3-methyl-pyrazol-1-yl]-3-pyridyl]methanol

CGI-I

Clinical Global Impression of Improvement

CGI-S

Clinical Global Impression of Illness Severity

GRID-HAMD-17

Grid format of the Hamilton Depression Rating Scale, 17 items

HADS

Hospital Anxiety and Depression Scale

HAMA

Hamilton Anxiety Rating Scale

LY2940094

BTRX-246040

MADRS

Montgomery-Asberg Depression Rating Scale

MDD

Major depressive disorder

MPS

Maier-Philipp subscale of the GRID-HAMD-17

N/OFQ

Nociceptin/orphanin FQ

Notes

Acknowledgments

We thank the book editors for the invitation to review the data on BTRX-246040. JMW also thanks former colleagues with whom he had the pleasure and honor to work with in characterizing LY2940094 (now BTRX-246040). Specifically, he thanks Michael Statnick, Miguel Toledo, Linda Rorick-Kehn, Xia Li, Scott Gleason, Keith Wafford, and Vanessa Barth from Eli Lilly and Company (Indianapolis, Indiana, the USA, and Windlesham, Surrey, the UK), Roberto Ciccocioppo (University of Camerino, Italy), and John Pintar (Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA).

JMW dedicates this review to the memory of creative and energetic chemist, devoted humanitarian, and friend Conception Pedregal, who led the chemistry effort to discover BTRX-246040.

Conflict of Interest

WJM and TLW are employees of and shareholders in BlackThorn Therapeutics which is actively evaluating BTRX-246040 for the treatment of neurobehavioral disorders.

References

  1. Argyropoulos SV, Nutt DJ (2013) Anhedonia revisited: is there a role for dopamine-targeting drugs for depression? J Psychopharmacol 27:869–877Google Scholar
  2. Beaulieu S, Saury S, Sareen J, Tremblay J, Schütz CG, McIntyre RS, Schaffer A (2012) Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force. Ann Clin Psychiatry 24:38–55Google Scholar
  3. Berthele A, Platzer S, Dworzak D, Schadrack J, Mahal B, Büttner A, Assmus HP, Wurster K, Zieglgänsberger W, Conrad B, Tölle TR (2003) [3H]-nociceptin ligand-binding and nociceptin opioid receptor mrna expression in the human brain. Neuroscience 121(3):629–640Google Scholar
  4. Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA (2016) The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom 85(5):270–288Google Scholar
  5. Chiu M, Vigod S, Rahman F, Wilton AS, Lebenbaum M, Kurdyak P (2018) Mortality risk associated with psychological distress and major depression: a population-based cohort study. J Affect Disord 234:117–123Google Scholar
  6. Ciccocioppo R, Economidou D, Fedeli A, Massi M (2003) The nociceptin/orphanin FQ/NOP receptor system as a target for treatment of alcohol abuse: a review of recent work in alcohol-preferring rats. Physiol Behav 79(1):121–128Google Scholar
  7. Cranford JA, Nolen-Hoeksema S, Zucker RA (2011) Alcohol involvement as a function of co-occurring alcohol use disorders and major depressive episode: evidence from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend 117(2-3):145–151Google Scholar
  8. de la Vega D, Piña A, Peralta FJ, Kelly SA, Giner L (2018) A review on the general stability of mood disorder diagnoses along the lifetime. Curr Psychiatry Rep 20:29Google Scholar
  9. Der-Avakian A, D’Souza MS, Potter DN, Chartoff EH, Carlezon WA Jr, Pizzagalli DA, Markou A (2017) Social defeat disrupts reward learning and potentiates striatal nociceptin/orphanin FQ mRNA in rats. Psychopharmacology 234:1603–1614Google Scholar
  10. Duman CH, Duman RS (2015) Spine synapse remodeling in the pathophysiology and treatment of depression. Neurosci Lett 601:20–29Google Scholar
  11. Gavioli EC, Calo’ G (2013) Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs. Pharmacol Ther 140(1):10–25Google Scholar
  12. Gomez AF, Barthel AL, Hofmann SG (2018) Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. Expert Opin Pharmacother 19(8):883–894Google Scholar
  13. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K (2004) Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 61:807–816Google Scholar
  14. Grant BF, Goldstein RB, Saha TD, Chou SP, Jung J, Zhang H, Pickering RP, Ruan J, Smith SM, Huang B, Hasin DS (2015) Epidemiology of DSM-5 alcohol use disorder results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiat 72:757–766Google Scholar
  15. Gu H, Hu D, Hong XR, Mao J, Cui Y, Hui N et al (2003) Changes and significance of orphanin and serotonin in patients with postpartum depression. Zhonghua Fu Chan Ke Za Zhi 38:727–728Google Scholar
  16. Hägele C, Schlagenhauf F, Rapp M, Sterzer P, Beck A, Bermpohl F, Stoy M, Ströhle A, Wittchen HU, Dolan RJ, Heinz A (2015) Dimensional psychiatry: reward dysfunction and depressive mood across psychiatric disorders. Psychopharmacology (Berl) 232(2):331–341Google Scholar
  17. Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM (2004) Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry 161:1256–1263Google Scholar
  18. Harmer CJ, Cowen PJ, Goodwin GM (2011) Efficacy markers in depression. J Psychopharmacol 25:1148–1158Google Scholar
  19. Hieronymus F, Emilsson JF, Nilsson S, Eriksson E (2016) Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry 21(4):523–530Google Scholar
  20. Iversen L (2005) The monoamine hypothesis of depression. In: Licinio J, Wong ML (eds) Biology of depression. Wiley-VCH, Weinheim, pp 71–86Google Scholar
  21. Jacobsen PL, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH (2015) A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry 76:575–582Google Scholar
  22. Jain R, Mahableshwarkar AR, Jacobsen PL (2013) A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol 16:313–321Google Scholar
  23. Jansen L, van Schijndel M, van Waarde J, van Busschbach J (2018) Health-economic outcomes in hospital patients with medical-psychiatric comorbidity: a systematic review and meta-analysis. PLoS One 13(3):e0194029Google Scholar
  24. Kallupi M, Scuppa G, de Guglielmo G, Calò G, Weiss F, Statnick MA, Rorick-Kehn LM, Ciccocioppo R (2017) Genetic deletion of the nociceptin/orphanin FQ receptor in the rat confers resilience to the development of drug addiction. Neuropsychopharmacology 42(3):695–706Google Scholar
  25. Katz MM, Koslow SH, Frazer A (1996) Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs. Depress Anxiety 4(6):257–267Google Scholar
  26. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, Frazer A (2004) Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 29(3):566–579Google Scholar
  27. Knowland D, Lim BK (2018) Circuit-based frameworks of depressive behaviors: the role of reward circuitry and beyond. Pharmacol Biochem Behav 174:42.  https://doi.org/10.1016/j.pbb.2017.12.010. [Epub ahead of print]CrossRefGoogle Scholar
  28. Koob GF (2015) The dark side of emotion: the addiction perspective. Eur J Pharmacol 753:73–87Google Scholar
  29. Kuzmin A, Madjid N, Johansson B, Terenius L, Ogren SO (2009) The nociceptin system and hippocampal cognition in mice: a pharmacological and genetic analysis. Brain Res 1305(Suppl):S7–S19Google Scholar
  30. Lambert C, Da Silva S, Ceniti AK, Rizvi SJ, Foussias G, Kennedy SH (2018) Anhedonia in depression and schizophrenia: a transdiagnostic challenge. CNS Neurosci Ther 24(7):615–623Google Scholar
  31. Madrid A, Smith DG, Alvarez-Horine S, Saljooqi K, Dagum P, Mahableshwarkar A (2017) T122 assessing anhedonia with quantitative tasks and digital and patient reported measures in a multi-center, double-blind trial with BTRX-246040 for the treatment of major depressive disorder (NCT03193398). In American College of Neuropsychopharmacology 56th annual meeting, Palm SpringsGoogle Scholar
  32. Mathews M, Gommoll C, Chen D, Nunez R, Khan A (2015) Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol 30:67–74Google Scholar
  33. Palpacuer C, Duprez R, Huneau A, Locher C, Boussageon R, Laviolle B, Naudet F (2018) Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction 113(2):220–237Google Scholar
  34. Pan Z, Grovu RC, Cha DS, Carmona NE, Subramaniapillai M, Shekotikhina M, Rong C, Lee Y, McIntyre RS (2017) Pharmacological treatment of cognitive symptoms in major depressive disorder. CNS Neurol Disord Drug Targets 16(8):891–899Google Scholar
  35. Peacock A, Leung J, Larney S, Colledge S, Hickman M, Rehm J, Giovino GA, West R, Hall W, Griffiths P, Ali R, Gowing L, Marsden J, Ferrari AJ, Grebely J, Farrell M, Degenhardt L (2018) Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction 113(10):1905–1926Google Scholar
  36. Post A, Smart TS, Jackson K, Mann J, Mohs R, Rorick-Kehn L, Statnick M, Anton R, O’Malley SS, Wong CJ (2016a) Proof-of-concept study to assess the nociceptin receptor antagonist LY2940094 as a new treatment for alcohol dependence. Alcohol Clin Exp Res 40(9):1935–1944Google Scholar
  37. Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M, Wafford K, McCarthy A, Barth V, Witkin JM (2016b) A selective nociceptin receptor antagonist to treat depression: evidence from preclinical and clinical studies. Neuropsychopharmacology 41(10):1803–1812Google Scholar
  38. Price JL, Drevets WC (2012) Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci 16(1):61–71Google Scholar
  39. Raddad E, Chappell A, Meyer J, Wilson A, Ruegg CE, Tauscher J, Statnick MA, Barth V, Zhang X, Verfaille SJ (2016) Occupancy of nociceptin/orphanin FQ peptide receptors by the antagonist LY2940094 in rats and healthy human subjects. Drug Metab Dispos 44(9):1536–1542Google Scholar
  40. Rekik K, Faria Da Silva R, Colom M, Pacifico S, Zaveri NT, Calo’ G, Rampon C, Frances B, Mouledous L (2017) Activation of nociceptin/orphanin FQ receptors inhibits contextual fear memory reconsolidation. Neuropharmacology 125:39–49Google Scholar
  41. Repousi N, Masana MF, Sanchez-Niubo A, Haro JM, Tyrovolas S (2018) Depression and metabolic syndrome in the older population: a review of evidence. J Affect Disord 237:56–64Google Scholar
  42. Rorick-Kehn LM, Ciccocioppo R, Witkin JM, Adams BL, Katner JS, Perry KW, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito A, Martínez-Grau M, Pedregal-Tercero C, Statnick MA (2016) A novel, orally-bioavailable nociceptin receptor antagonist, LY2940094, reduces ethanol self-administration and ethanol-seeking in animal models. Alcoholism Clin Exp Res 40(5):945–954Google Scholar
  43. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D et al (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR_D report. Am J Psychiatry 163:1905–1917Google Scholar
  44. Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61:275–291Google Scholar
  45. Soyka M, Müller CA (2018) Pharmacotherapy of alcoholism – an update on approved and off-label medications. Expert Opin Pharmacother 18(12):1187–1199Google Scholar
  46. Spampinato S, Baiula M, Calienni M (2007) Agonist-regulated internalization and desensitization of the human nociceptin receptor expressed in CHO cells. Curr Drug Targets 8(1):137–146Google Scholar
  47. Statnick MA, Chen Y, Ansonoff M, Witkin JM, Rorick-Kehn L, Suter TM, Song M, Hu C, Lafuente C, Jiménez A, Benito A, Diaz N, Martínez-Grau MA, Toledo MA, Pintar JE (2016) A novel nociceptin receptor antagonist LY2940094 inhibits excessive feeding behavior in rodents: a possible mechanism for the treatment of binge eating disorder. J Pharmacol Exp Ther 356(2):493–502Google Scholar
  48. Toledo MA, Pedregal C, Lafuente C, Diaz N, Martinez-Grau MA, Jiménez A, Benito A, Torrado A, Mateos C, Joshi EM, Kahl SD, Rash KS, Mudra DR, Barth VN, Shaw DB, McKinzie D, Witkin JM, Statnick MA, Toledo MA, Pedregal C, Lafuente C, Diaz N, Martinez-Grau MA, Jiménez A, Benito A, Torrado A, Mateos C, Joshi EM, Kahl SD, Rash KS, Mudra DR, Barth VN, Shaw DB, McKinzie D, Witkin JM, Statnick MA (2014) Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7′-thieno[2,3-c]pyran) scaffold. J Med Chem 57(8):3418–3429Google Scholar
  49. Tranter R, Bell D, Gutting P, Harmer C, Healy D, Anderson IM (2009) The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients. J Affect Disord 118:87–93Google Scholar
  50. Ulbaldi M, Cannella N, Ciccocioppo R (2016) Emerging targets for addiction neuropharmacology: from mechanisms to therapeutics. Prog Brain Res 224:251–284Google Scholar
  51. USDHHS (2015) Alcoholism: developing drugs for treatment – guidance for industry. Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM433618.pdf
  52. Vitale G, Filaferro M, Micioni Di Bonaventura MV, Ruggieri V, Cifani C, Guerrini R, Simonato M, Zucchini S (2017) Effects of [Nphe1, Arg14, Lys15] N/OFQ-NH2 (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress. J Psychopharmacol 31(6):691–703Google Scholar
  53. Wang LN, Liu LF, Zhang JX, Zhao GF (2009) Plasma levels of nociceptin/orphanin FQ in patients with bipolar disorders and healthy adults. Zhonghua Yi Xue Za Zhi 89:916–918Google Scholar
  54. Witkin JM, Statnick MA, Rorick-Kehn LM, Pintar JE, Ansonoff M, Chen Y, Tucker RC, Ciccocioppo R (2014) The biology of nociceptin/orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. Pharmacol Ther 141(3):283–299Google Scholar
  55. Witkin JM, Rorick-Kehn LM, Benvenga MJ, Adams BL, Gleason SD, Knitowski KM, Li X, Chaney S, Falcone JF, Smith JW, Foss J, Lloyd K, Catlow JT, McKinzie DL, Svensson KA, Barth VN, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito A, Pedregal C, Martínez-Grau MA, Post A, Ansonoff MA, Pintar JE, Statnick MA (2016) Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors. Pharmacol Res Perspect 4(6):e00275Google Scholar
  56. Witkin JM, Knutson DE, Rodriguez GJ, Shi S (2018) Rapid-acting antidepressants. Curr Pharm Des 24:2556–2563Google Scholar
  57. You C, Vandegrift B, Brodie MS (2018) Ethanol actions on the ventral tegmental area: novel potential targets on reward pathway neurons. Psychopharmacology 235(6):1711–1726Google Scholar
  58. Zaveri NT (2016) Nociceptin opioid receptor (NOP) as a therapeutic target: progress in translation from preclinical research to clinical utility. J Med Chem 59(15):7011–7028Google Scholar
  59. Zhang LL, Zheng HP, Ma C, He ZG, Zheng CD (2009) The plasma orphanin FQ in patients with depression before and after treatment. Chin J Psychiatry 42:138–144Google Scholar
  60. Zimmerman M, Martinez JH, Young D, Chelminski I, Dalrymple K (2013) Severity classification on the Hamilton Depression Rating Scale. J Affect Disord 150:384–388Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Jeffrey M. Witkin
    • 1
    Email author
  • Tanya L. Wallace
    • 2
  • William J. Martin
    • 2
  1. 1.Witkin Consulting GroupCarmelUSA
  2. 2.BlackThorn TherapeuticsSan FranciscoUSA

Personalised recommendations